Treatment duration
In patients with MBC, Herceptin is approved for use until disease progression. The benefits of continuing Herceptin therapy after disease progression, typically changing its combination partner, are currently under investigation in a number of clinical trials.
Full details on current indications for Herceptin can be found in the European
Summary of Product Characteristics.